BWL
CRSP icon

Bogart Wealth LLC’s CRISPR Therapeutics CRSP Stock Holding History

Bogart Wealth LLC’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.18K Hold
150
– – ﹤0.01% 1057
2026
Q1 		$7.14K Hold
150
– – ﹤0.01% 977
2025
Q4 		$7.87K Sell
150
-500
-77% -$29.9K ﹤0.01% 907
2025
Q3 		$42.1K Buy
650
+500
+333% +$28.7K ﹤0.01% 500
2025
Q2 		$7.3K Buy
150
+50
+50% +$1.94K ﹤0.01% 853
2025
Q1 		$3.4K Buy
+100
New +$4.24K ﹤0.01% 975
2024
Q4 		– Sell
-500
Closed -$23.5K – 1348
2024
Q3 		$23.5K Hold
500
– – ﹤0.01% 528
2024
Q2 		$27K Buy
+500
New +$28.9K ﹤0.01% 489
2023
Q2 		– Sell
-6
Closed -$271 – 1061
2023
Q1 		$271 Hold
6
– – ﹤0.01% 1067
2022
Q4 		$244 Sell
6
-44
-88% -$2.33K ﹤0.01% 953
2022
Q3 		$3K Buy
+50
New +$3.62K ﹤0.01% 766

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bogart Wealth LLC's CRSP Position: Q2 2026 in Review

Bogart Wealth LLC held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 150 shares worth $8.18K. The position accounts for ﹤0.01% of the portfolio, ranked #1057.

Bogart Wealth LLC first reported a position in CRSP in Q3 2022 and has held it in 11 quarters since. The position peaked at $42.1K in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Bogart Wealth LLC held 150 shares of CRISPR Therapeutics worth $8.18K as of Q2 2026.
  • Bogart Wealth LLC left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Bogart Wealth LLC's portfolio in Q2 2026, its #1057 holding.
  • Bogart Wealth LLC first reported a position in CRISPR Therapeutics in Q3 2022 and has held it in 11 quarters since.
  • Bogart Wealth LLC's CRISPR Therapeutics position peaked at $42.1K in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Bogart Wealth LLC's 13F filing for Q2 2026, filed 24 Jul 2026.